Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease

Abstract

LINKED CONTENT This article is linked to Volkers et al papers. To view these articles, visit https://doi.org/10.1111/apt.17153 and https://doi.org/10.1111/apt.17407

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study

“…Safety concerns have been raised regarding switch back to IV once being established on SC treatment. 22 , 23 In the present study, 4 patients switched back to IV due to ISRs, and 3 of these patients experienced AEs at consecutive infusions, 1 case leading to discontinuation of VDZ. Our observations are consistent with observations made by Volkers et al, where 1 out of 4 patients switching back to IV due to ISRs had to discontinue VDZ.…”

“… 4 , 5 , 15–18 Yet, recently published reports disclosed that some patients with AEs on SC VDZ, experienced AEs also when switching back to IV treatment. 22 , 23 Thus, further safety data when switching back to IV VDZ are needed.…”

Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients—authors' reply

“…We read with great interest the letter by Richard et al 1 in relation to our recently published study reporting real-world experience of switching from intravenous (IV) to biweekly subcutaneous (SC) vedolizumab maintenance treatment for patients with inflammatory bowel diseases (IBD). 2 Richard et al reported seven (out of a total of 10) patients who switched back from SC to IV vedolizumab due to injection site reactions and then developed infusion reactions after IV vedolizumab administration.…”